<DOC>
	<DOCNO>NCT00439517</DOCNO>
	<brief_summary>This exploratory study compare activity safety 400 patient previously untreated metastatic carcinoma colon treat UFOX ( combination regimen UFT® ( Tegafur plus Uracil ) , Oxaliplatin , Folinic Acid ) plus Cetuximab FOLFOX-4 ( combination regimen 5 Fluorouracil ( 5-FU ) , Oxaliplatin Folinic Acid ) plus Cetuximab )</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria Signed write informed consent Inpatient outpatient ≥ 18 year age Diagnosis histologically confirm adenocarcinoma colon rectum First occurrence metastatic disease ( curatively resectable ) Presence least one lesion measurable uni dimensionally computerise tomography ( CT ) scan magnetic resonance imaging ( MRI ) . ( Target lesion ( ) must lie within irradiated area ) Life expectancy ≥ 3 month Karnofsky performance status ≥ 60 , study entry White blood cell count ( WBC ) ≥ 3 x 10^9/L , neutrophil ≥ 1.5 x 10^9/L , platelet ≥ 100 x 10^9/L , hemoglobin ≥ 9 g/dL Aspartate transaminase alanine transaminase ≤ 2.5 x Upper Limit Normal ( ULN ) ( ≤ 5 x ULN liver metastasis present ) Normal serum creatinine ( case elevate creatinine , label ethylenediaminetetraacetic acid clearance ≥ 65 mL/min acceptable ) Effective contraception male female subject risk conception exists Tumor biopsy archive sample available Exclusion criterion : Brain metastasis and/or leptomeningeal disease ( know suspect ) Previous chemotherapy colorectal cancer except adjuvant treatment progression disease document &gt; 6 month end adjuvant treatment . Previous oxaliplatinbased chemotherapy Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior randomization Concurrent previous chronic systemic immune therapy , target therapy , antivascular epithelial growth factor ( VEGF ) therapy , epidermal growth factor receptor ( EGFR ) pathway target therapy indicate study protocol Concurrent hormonal therapy indicate study protocol except physiologic replacement contraception Clinically relevant coronary artery disease , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Peripheral neuropathy &gt; grade 1 Known hypersensitivity reaction component treatment . Any concurrent malignancy basal cell cancer skin , preinvasive cancer cervix . ( Subjects previous malignancy without evidence disease ≥ 5 year allow enter study ) Pregnancy ( absence confirm ßhuman chorionic gonadotrophin test ) lactation period Known drug abuse/alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit subject complete study sign meaningful inform consent Participation another clinical study within 30 day randomization Significant disease , investigator 's opinion , would exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Untreated</keyword>
</DOC>